Attovia Therapeutics, Inc. (NASDAQ:ATTO) Short Interest Up ∞ in August

Attovia Therapeutics, Inc. (NASDAQ:ATTO) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 511,865 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average daily volume of 732,925 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.2% of the company’s shares are sold short.

Insiders Place Their Bets

In related news, major shareholder Redmile Group, Llc purchased 400,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, with a total value of $6,800,000.00. Following the purchase, the insider owned 1,182,854 shares of the company’s stock, valued at $20,108,518. This trade represents a 51.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Goldman Sachs Group Inc acquired 500,000 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were bought at an average price of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the insider owned 3,020,632 shares in the company, valued at approximately $51,350,744. This trade represents a 19.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 2,740,587 shares of company stock worth $47,269,979 over the last three months. Company insiders own 0.99% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. boosted its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

Attovia Therapeutics Price Performance

Attovia Therapeutics stock opened at $20.70 on Friday. Attovia Therapeutics has a 52 week low of $16.15 and a 52 week high of $24.32.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.